Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the UK / NCT07796165
Starting soon Not applicable

SNIP follow-on Case Series Using v3 Device

NCT07796165 · tracked via the Priya Life Science UK tracker
Sponsor
Europa Life Sciences Limited
Phase
Not applicable
Started
2026-10-01
Last updated
2026-09-04

Condition(s) studied

Ankyloglossia

Investigational drug(s) / intervention(s)

Frenectomy of anterior ankylogossia using the novel device

Frenectomy of anterior ankylogossia using the novel device: Patient treated using the novel device under study

Study summary

Case series of infants with anterior ankyloglossia being treated by the Sublingual Neonatal Incision Platform device

Eligibility

Sex
ALL
Min age
1 Week
Max age
12 Weeks
Healthy volunteers
No
Inclusion Criteria: * Ankyloglossia requiring intervention Exclusion Criteria: * Concomitant morphological variation in the oral cavity which could compromise frenotomy * Blood dyscrasia * Immunocompromise

Primary outcome measure(s)

  • Clinician Device Experience — Immediately post-op
    The physician will be asked to rate following attributes of the use of the tool, in Likert scale of 1-5; Whether the device felt intuitive, whether they felt more confident using this device, whether they would use this device again for a similar release?

Trial sites (1)

FacilityCityRegionStatus
Tunbridge Wells Hospital Pembury Royal Tunbridge Wells United Kingdom

More Europa Life Sciences Limited trials in the UK

Case Series of Infants With Anterior Ankyloglossia Being Treated by the Sublingual Neonatal Incision Platform Device Active, not recruiting

Other trials for the same condition

Case Series of Infants With Anterior Ankyloglossia Being Treated by the Sublingual Neonatal Incision Platform Device Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07796165 on ClinicalTrials.gov ↗ ← All trials in the UK